Free tools Windows power users keep installed
One-click scans. No signup required.
The sound way to evaluate a health insurer is to work from operations to valuation: read the latest reported results and management outlook, build an earnings bridge from premiums, medical costs, expenses and capital, test the assumptions against utilization and membership evidence, inspect reserves and regulatory constraints, then compare a clearly defined P/E with relevant peers. A low multiple is not automatically cheap, and a high medical-loss ratio is not meaningful without its product mix, accounting definition and underlying causes.
Start by identifying the business you are actually valuing
Health insurers can look similar on a stock screen while carrying very different economic risks. Before calculating a multiple, determine which businesses generate the company’s earnings and how those businesses are changing.
As an Amazon Associate I earn from qualifying purchases.
Map the segments and payer exposure
Read the business descriptions in the latest Form 10-K, then update the picture with the latest Form 10-Q. Separate Medicare Advantage, Medicaid, Affordable Care Act marketplace plans, employer or commercial coverage and any non-insurance operations. Government-program exposure brings different rate-setting, risk-adjustment, quality-rating and policy risks than employer coverage. A company growing in Medicaid may deserve different assumptions from one growing in Medicare Advantage, even if both report premium growth.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
The SEC’s Investor.gov guide explains that a 10-K covers operations, financial results, liquidity and capital resources, known trends and uncertainties, risk factors and audited financial statements. Use those sections together rather than relying on an earnings-release headline: Investor.gov’s “How to Read a 10-K/10-Q” guide.
#1 Best Overall
List the economic exposures that can move earnings
- Premium rates and other operating revenue, including whether pricing reflects expected medical-cost inflation.
- Membership growth, attrition and changes in the mix of healthier and sicker members.
- Utilization of physician, hospital, pharmacy and other services.
- Acuity, or the expected costliness of enrolled members.
- Risk-adjustment transfers and changes in government formulas or contracts.
- Benefit design, quality ratings and related bonus or penalty payments.
- Administrative costs, technology spending and acquisition or restructuring costs.
- Investment income, taxes, share count, debt and regulated-subsidiary capital needs.
This map prevents a common mistake: treating revenue or membership growth as proof of better earnings. Growth can reduce profitability if prices lag claims or if new members are concentrated in less-profitable products.
Build an earnings bridge from operating drivers
Construct a period-by-period bridge that shows how revenue becomes earnings. At minimum, track premium and other operating revenue, medical costs, the medical or benefit cost ratio, administrative expense ratio, investment income, taxes and diluted shares.
Revenue and membership
Record premium revenue separately from investment income and other items. Reconcile enrollment changes with premium growth: a higher premium per member can reflect rate increases, richer benefits, acuity or a shift in product mix rather than underlying volume. Read management’s discussion of pricing, membership, benefit changes and government rates to identify what is recurring.
Medical or benefit cost ratio
The ratio generally compares medical or benefit costs with premium revenue, but companies use different names, scopes and adjustments. A lower ratio can support margin, yet a direct comparison is unsafe unless the numerator, denominator, segment mix and accounting period match. Examine whether a change came from utilization, acuity, provider prices, pharmacy costs, risk adjustment, benefit design or reserve development.
Administrative efficiency and below-the-line items
Track the administrative expense ratio and explain unusual changes. A temporary cost reduction, a delayed investment or an acquisition-related charge should not be projected indefinitely. Then add investment income, interest, taxes and diluted shares. Buybacks can lift EPS even when operating profit is flat, while new shares or acquisition financing can dilute it.
Separate growth from margin
Write the bridge in plain language: “membership increased,” “premium per member changed,” “medical cost per member moved,” “administrative cost per member changed,” and “share count changed.” This makes it possible to see whether an earnings forecast depends on more members, better pricing, lower utilization, favorable reserve development or financial engineering.
Read guidance as a set of assumptions, not a result
Management guidance is an expectation. Preserve the history of the forecast so that a current number is not mistaken for a stable plan.
Recommended Free Tools
Create a guidance timeline
- Record the current full-year GAAP EPS outlook and any adjusted EPS outlook.
- Record the preceding outlook from the prior release or filing.
- Place the latest quarter’s actual revenue, ratio, operating income and EPS beside both outlooks.
- Quote the company’s stated reasons for any raise, maintenance or cut.
- Mark each reason as likely temporary, recurring, controllable or dependent on an outside party.
Ask what medical-cost trend, membership growth, acuity, pricing, risk adjustment and benefit assumptions are embedded in the midpoint or floor. A forecast that is maintained after a weak quarter may rely on improvement later in the year; identify the quarter and operating measure that must improve.
Keep GAAP and adjusted EPS separate
Adjusted EPS may exclude items that management considers unusual, but exclusions can differ between companies and periods. Do not compare one insurer’s adjusted forward EPS with another insurer’s trailing GAAP EPS. Read the reconciliation and decide whether excluded costs are genuinely nonrecurring. Present both measures when they tell different stories.
Current illustration: Humana’s 2026 outlook change
In its July 29, 2026 second-quarter release, Humana revised full-year 2026 GAAP EPS guidance to “at least $6.52” from “at least $8.36,” while affirming adjusted EPS guidance of “at least $9.00.” The company said the expected year-over-year adjusted EPS decline reflected the Star Ratings headwind for Bonus Year 2026, net of mitigation. The figures are company-specific, not industry benchmarks. The release is available at Humana’s July 29, 2026 second-quarter results and guidance.
Rank #3
The analytical task is to preserve the GAAP-versus-adjusted distinction, quantify the ratings effect if disclosed, and decide whether the mitigation is a one-year action or a repeatable capability. Humana President and CEO Jim Rechtin said, “When we get the clinical care right and run the business more efficiently, everything else follows—stronger earnings and better health and experiences for the people we serve.” That is management’s stated operating philosophy, not independent evidence that the forecast will be achieved.
Run explicit base and downside cases
Do not silently extend management’s midpoint. Define the variables that matter and change them deliberately:
| Case | Medical-cost trend | Membership and mix | Other assumptions | Purpose |
|---|---|---|---|---|
| Base | Management’s stated trend | Guided enrollment and acuity | Guided pricing, risk adjustment and expenses | Tests whether the published outlook is internally coherent |
| Downside | Higher utilization or provider cost than guided | Less favorable mix or slower enrollment | Lower risk-adjustment benefit, weaker ratings or higher expenses | Measures earnings sensitivity to the main operating risk |
| Upside | Trend at or below guidance | Better retention or mix | Favorable pricing, ratings or operating leverage | Shows what must go right; it is not a target |
State every change. If a downside case assumes a one-percentage-point increase in the medical-cost ratio, show how that flows through pre-tax income, taxes and diluted EPS rather than presenting an unexplained percentage haircut.
Inspect claims, reserves and regulatory minimums
Claims are estimated after services occur, so current earnings include judgments about claims incurred but not yet reported (IBNR), completion patterns and risk-adjustment settlements. Reserve quality often determines whether a favorable quarter persists.
What to examine in the filings
- Medical claims liabilities and the methods used to estimate them.
- Prior-period reserve development: whether earlier estimates proved too high or too low.
- IBNR assumptions, completion factors and any disclosed sensitivity.
- Risk-adjustment receivables, payables and true-ups.
- Premium deficiency reserves when expected future costs exceed expected premiums.
- Whether a ratio improvement came from current-period operations or release of earlier reserves.
Favorable development can boost the current period while reducing a future benefit; unfavorable development can reverse earlier optimism. Ask whether assumptions changed, whether development is concentrated in one product and whether the company identifies a recurring trend.
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Clear out junk files and repair common Windows errors3Scan for outdated or missing drivers - takes under a minuteMinimum-loss-ratio rules are product-specific
Alignment Healthcare’s 2025 Form 10-K describes an 85% minimum annual medical-loss ratio for the Medicare Advantage plans covered by that filing. If the minimum is not met, a portion of premiums may have to be remitted to the federal government. This requirement applies to the stated plans and should not be generalized to every product line or insurer. The filing is at Alignment Healthcare’s 2025 Form 10-K.
Use the ratio with its drivers
Molina Healthcare reported a 91.7% consolidated medical-cost ratio for 2025, compared with 89.1% in 2024. It attributed the increase mainly to utilization above expectations and acuity shifts, and described the 2025 ratio as above its long-term target range. The filing is available at Molina Healthcare’s 2025 Form 10-K. The useful conclusion is not that one ratio is universally “good” or “bad,” but that the direction, causes, target and product mix must be understood together.
Check capital, cash and balance-sheet constraints
Read the liquidity and capital-resources discussion and the regulated-subsidiary disclosures. An insurer’s parent company may hold cash that cannot freely be moved from subsidiaries that must satisfy statutory capital requirements.
Items to reconcile
- Debt maturities, interest expense and holding-company cash.
- Statutory capital or risk-based-capital disclosures for regulated subsidiaries.
- Dividend restrictions and required capital contributions.
- Claims liabilities and working-capital timing.
- Cash generation after required capital, not merely before it.
- Whether buybacks, dividends or acquisitions rely on temporary cash or sustainable operating cash flow.
There is no single cross-company capital threshold established by the figures discussed here. Use each issuer’s filings and the applicable state and federal regulatory context. Treat parent cash, regulated-subsidiary capital and short-term working capital as different resources.
Choose an earnings denominator before using P/E
The P/E ratio is stock price divided by earnings per share. Investor.gov describes its use for comparing a stock with its own history or with other companies at Investor.gov’s P/E ratio explanation. The arithmetic is simple; selecting a consistent EPS denominator is not.
Best Value
Specify the four choices
- Trailing or forward: trailing EPS uses reported past earnings; forward EPS uses an estimate for a stated future period.
- GAAP or adjusted: GAAP follows the accounting rules; adjusted EPS reflects the company’s reconciliation and exclusions.
- Period end and date: identify the share-price date and whether EPS covers the last twelve months, current fiscal year or next fiscal year.
- Diluted share count: confirm that the denominator reflects options, convertibles, buybacks and expected issuance consistently.
Write the calculation beside the quote: P/E = share price ÷ diluted EPS for the specified period. A forward multiple changes every time the share price or earnings estimate changes, so date both inputs.
Illustrative scenario math
The following is a hypothetical example, not a company forecast. At a $100 share price, EPS of $10 produces a 10.0x P/E; EPS of $8 produces a 12.5x P/E. If the share price stays constant while earnings fall, the stock becomes more expensive on the earnings measure even though its price did not rise.
| Illustrative case | Share price | EPS basis | Implied P/E |
|---|---|---|---|
| Base | $100 | $10.00 | 10.0x |
| Downside | $100 | $8.00 | 12.5x |
| Upside | $100 | $11.00 | 9.1x |
Use the same EPS definition and date for every peer. If a company does not disclose a directly comparable figure, label the cell “not stated” and do not fill the gap with a different accounting basis.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCompare insurers on risk-adjusted dimensions
A peer multiple is useful only after business models and earnings risks are aligned. Compare the following axes rather than ranking companies by P/E alone.
| Axis | Questions to answer | Why it affects valuation |
|---|---|---|
| Government versus commercial mix | What share comes from Medicare Advantage, Medicaid, marketplace and employer products? | Rate-setting, policy, risk-adjustment and quality-rating exposure differ. |
| Membership and premium growth | Is growth volume-driven, price-driven or mix-driven? | Growth without adequate pricing can reduce earnings. |
| Medical-cost trend | Are utilization, acuity, provider prices or pharmacy costs moving? | Small ratio changes can have large effects on margin. |
| Administrative efficiency | Are expense changes structural, temporary or investment-related? | One-time savings should not receive a permanent valuation premium. |
| Pricing and rate adequacy | Do approved rates cover expected costs and benefits? | Insufficient rates create future margin pressure. |
| Reserve and risk-adjustment uncertainty | How large are development swings and true-ups? | Higher uncertainty warrants a more cautious earnings multiple. |
| Capital and leverage | How much cash is trapped in regulated entities, and when is debt due? | Capital needs can limit buybacks and distributions. |
| Earnings growth and volatility | How often has guidance changed, and how variable are results? | Predictability can justify a different multiple from headline growth. |
| Valuation basis | Are all P/Es based on the same date, period and GAAP or adjusted EPS? | Mixed denominators create false cheapness or expensiveness. |
Use published figures as evidence, not as automatic conclusions
Recent company disclosures show why context matters:
| Company and date | Reported figure | Interpretation to investigate | Source |
|---|---|---|---|
| Centene, second-quarter 2026 results, July 28, 2026 | $20.3 billion in medical claims liabilities; total-revenue guidance of $193.5 billion to $197.5 billion | Reconcile the liability with claims estimates, cash needs and the revenue assumptions supporting guidance. | Centene release |
| Oscar Health, first-half 2026 results | Second-quarter 2026 MLR of 79.2% versus 91.1% in second-quarter 2025; operating earnings of $388.6 million versus an operating loss of $230.5 million | Oscar said the prior-year quarter included the first-half 2025 effect of a risk-adjustment true-up driven by higher average market morbidity, so the year-over-year comparison needs that context. | Oscar Health release |
| Molina Healthcare, 2025 Form 10-K | 2025 consolidated MCR of 91.7% versus 89.1% in 2024 | The increase was attributed mainly to utilization above expectations and acuity shifts; Molina described the ratio as above its long-term target range. | Molina filing |
| Alignment Healthcare, 2025 Form 10-K | 85% minimum annual MLR for the Medicare Advantage plans described | Failure to meet the minimum may require remittance of a portion of premiums to the federal government; scope is limited to the plans described. | Alignment filing |
| Humana, July 29, 2026 | FY 2026 GAAP EPS guidance of at least $6.52, down from at least $8.36; adjusted EPS guidance affirmed at at least $9.00 | Humana cited the Star Ratings headwind for Bonus Year 2026, net of mitigation; preserve the GAAP and adjusted distinction. | Humana release |
These dated figures should be replaced by the latest filings when making a current decision. They illustrate analytical methods, not universal industry benchmarks.
A repeatable workflow for an investor’s spreadsheet
- Set the valuation date. Record the share price, shares outstanding and the latest available filing date.
- Define the business mix. Copy segment membership, premium revenue and government-program exposure from the 10-K and latest 10-Q.
- Build three years of operating history. Enter revenue, medical costs, medical or benefit ratio, administrative expenses, operating income, investment income, taxes and diluted shares.
- Bridge the latest quarter. Explain every material year-over-year change using utilization, acuity, pricing, membership, risk adjustment, benefit design and reserve development.
- Capture guidance history. Record prior and current GAAP and adjusted EPS outlooks, including the date and any range or “at least” floor.
- Translate guidance into assumptions. Identify the implied medical-cost trend, membership, pricing, ratings, risk-adjustment and expense assumptions.
- Test scenarios. Build base and downside cases with explicit changes to the highest-impact drivers; calculate resulting EPS rather than applying an unexplained discount.
- Audit reserves. Review IBNR, prior-period development, risk-adjustment balances and premium deficiency reserves.
- Audit capital. Separate parent cash from regulated-subsidiary capital, review debt and dividend restrictions, and estimate cash available after requirements.
- Select the EPS denominator. Choose trailing or forward and GAAP or adjusted; document the period, date and diluted share count.
- Compare peers consistently. Align business mix, growth, ratio definitions, leverage, capital needs and EPS basis before reading relative P/E.
- Write the decision rule. State which assumptions must hold for the current multiple to be attractive and what evidence would invalidate the thesis.
Common valuation mistakes and how to correct them
- Using one medical-loss ratio in isolation: trace the ratio to utilization, acuity, product mix and reserve development.
- Quoting the newest guidance without the old guidance: show the revision and explain each changed assumption.
- Mixing GAAP and adjusted EPS: label the denominator and read the reconciliation.
- Treating a reserve release as recurring profit: separate current-period operations from prior-period development.
- Assuming all cash is distributable: distinguish holding-company cash from regulated capital and required contributions.
- Calling a low peer P/E undervalued: check government exposure, growth, volatility, leverage, capital needs and forecast risk first.
- Ignoring share-count changes: use diluted shares and model buybacks or issuance explicitly.
- Turning a scenario into a target price: present the price as an output of stated assumptions, not an objective fact.
What a defensible conclusion looks like
A defensible conclusion links valuation to operating evidence: “At this share price, the stock trades at X times the specified forward GAAP EPS. That valuation requires the medical-cost ratio to remain within the stated range, membership and pricing assumptions to hold, reserve development to stay ordinary and capital requirements to leave the projected cash available. Under the defined downside case, EPS falls to Y and the multiple rises to Z.” This format makes clear what is measured, what is forecast and what could go wrong.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
